Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway

Journal of Chemotherapy

Volumn 21, Issue 4, 2009, Pages 396-402

  Ikegaya, S ^a   Inai, K ^a   Iwasaki, Hiromichi ^a,b   Naiki, H ^a   Ueda, T ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NONE   (Japan)

Author keywords

Azithromycin; HSP 70; Monocytes; p38 MAPK; TNF

Indexed keywords

AZITHROMYCIN; HEAT SHOCK PROTEIN 70; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KNK 437; LIPOPOLYSACCHARIDE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OFLOXACIN; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELLULAR STRESS RESPONSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INCUBATION TIME; MONOCYTE; PROTEIN PHOSPHORYLATION; THP 1 CELL;

EID: 70349197594     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.4.396     Document Type: Article

References (46)

1. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232(4753):977-980 (Pubitemid 16085400)
2. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351(9107): 929-933
3. Cohen J, Abraham E. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis. 1999; 180(1): 116-121 (Pubitemid 29293925)
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6):864-874
5. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin. 2001; 19(4): 617-635
6. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004; 140(2):218-225 (Pubitemid 38500336)
7. Roche Y, Gougerot-Pocidalo MA, Fay M, Forest N, Pocidalo JJ. Macrolide and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J. Antimicrob. Chemother. 1986; 17: 195-203.
8. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989; 159: 966-973. (Pubitemid 19113085)
9. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effect of antibiotics: literature review. Infection 1996; 24: 275-291. (Pubitemid 26273294)
10. Stevens DL. Immune modulatory effects of antibiotics. Curr Opin Infect Dis. 1996; 9: 165-169
11. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996;40(6):1366-1370 (Pubitemid 26000565)
12. Korzeniowski OM. Effects of antibiotics on the mammalian immune system. Infect Dis Clin North Am. 1989; 3: 469-78.
13. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol. 2000; 20;410(1):83-92. (Pubitemid 32008133)
14. Williams JD. Spectrum of activity of azithromycin. Eur J Clin Micrb Infect Dis 1991; 10; 813-820
15. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 1989; 33(3): 277-282.
16. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91 (suppl.3A): 3A5S-3A11S.
17. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis. 1991; 10(10):828-833
18. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther. 1994; 32(7):356-360 (Pubitemid 24212081)
19. Retsema JA, Bergeron JM, Girard D, Milisen WB, Girard AE. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993; 31 Suppl E:5-16. (Pubitemid 23220183)
20. Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999; 11(2):121-32.
21. Yokota S, Kitahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000; 60(11): 2942-2948 (Pubitemid 30395819)
22. Inai K, Tsutani H, Yamauchi T, Fukushima T, Iwasaki H, Imamura S, et al. Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil. Leuk Res. 2000; 24(9): 761-768 (Pubitemid 30649696)
23. Inai K, Tsutani H, Yamauchi T, Huberman E, Nakamura T, Ueda T. Differentiation induction in non-lymphocytic leukemia cells upon treatment with mizoribine. Int J Hematol. 1997; 66(3): 335-344 (Pubitemid 27495991)
24. Wang JH, Doyle M, Manning BJ, Di Wu Q, Blankson S, Redmond HP. Induction of bacterial lipoprotein tolerance is associated with suppression of toll-like receptor 2 expression. J Biol Chem. 2002; 277(39): 36068-36075
25. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP-70 stimulates cytokine production through a CD 14-dependent pathway, demonstrating its dual role as a shaperone and cytokine. Nature Med, 2000; 6, 4: 435-442. (Pubitemid 30208161)
26. Vega VL, De Maio A. Geldanamycin treatment ameliorates the response to LPS in murine macrophages by decreasing CD14 surface expression. Mol Biol Cell 2003; 14(2): 764-773 (Pubitemid 36237030)
27. Briant D, Ohan N, Heikkila JJ. Effect of herbimycin A on hsp30 and hsp70 heat shock protein gene expression in Xenopus cultured cells. Biochem Cell Biol. 1997; 75(6): 777-782 (Pubitemid 127733233)
28. Housby JN, Cahill CM, Chu B, Prevelige R, Bickford K, Stevenson MA, et al. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999; 11(5): 347-358 (Pubitemid 29233968)
29. Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol. 2004; 286(4): C739-44. (Pubitemid 38543800)
30. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding proteins. Science. 1990; 249(4975): 1431-1433 (Pubitemid 20341908)
31. Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995; 155(1): 6-8.
32. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, et al. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol. 2000; 164(7): 3471-3475 (Pubitemid 30169795)
33. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol. 2000; 164(7): 3476-3479 (Pubitemid 30169796)
34. Manthey CL, Wang SW, Kinney SD, Yao Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol 1998; 64(3): 409-417 (Pubitemid 28409249)
35. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem 2001; 276, 9: 6666-6674. (Pubitemid 37373531)
36. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22, 631-677
37. Tracey KJ. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ Shock 1991; 35(2):123-128
38. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491-503. (Pubitemid 24985968)
39. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988; 57: 505-518 (Pubitemid 18171400)
40. Bauss F, Droge W, Mannel DN. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun. 1987; Jul 55(7): 1622-1625
41. Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest. 1987; 56(6): 583-590 (Pubitemid 17095929)
42. Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol. 1992; 263(1 Pt 1): C1-16.
43. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1829-1832 (Pubitemid 28311266)
44. Schoni MH. Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med Wkly. 2003; 133(21-22):297-301. (Pubitemid 36903756)
45. Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am J Respir Med. 2002; 1(4): 235-41.
46. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51(3):975-981 (Pubitemid 46355283)